University of Texas Health Science Center
Jay-Jiguang Zhu, MD, PHD, is the Director of Neuro-oncology Service and professor at Neurosurgery Department and adjunct professor in Neurology Department in University of Texas Health Science Center in Houston (UTHealth) and Memorial Hermann at Texas Medical Center.
He is board certified neurologist by American Board of Psychiatry and Neurology and neuro-oncologist by United Council for Neurologic Subspecialties in Neuro-oncology subspecialty.
Dr. Zhu earned his medical degree (MDCM) from McGill University in Montreal, Quebec, Canada and completed his residency training in neurology at Tufts Medical Center, Tufts University, School of Medicine in Boston. He subsequently completed his fellowship in neuro-oncology at Massachusetts General Hospital, Harvard Medical School in Boston.
Dr. Zhu received his doctorate (PhD) in the field of molecular biology at the State University of New York in Buffalo, N.Y. and Roswell Park Cancer Institute, and completed his post-doctoral training in brain tumor research at Children’s Hospital, Brigham and Woman’s Hospital, Harvard Medical School.
Prior to taking the position at the Director of Neuro-oncology service at UTHealth/Memorial Hermann at TMC in 2010, Dr. Zhu was on faculty of Tufts Medical Center and Tufts University School of Medicine where he served as an assistant professor and attending in neurology. He build and expand neuro-oncology at UTHealth and Memorial Hermann.
His many honors and awards include CUSBEA scholar (China and United States Biochemistry Exchange Application), Massachusetts Medical Society Scholarships, the Abby H. Shevitz, M.D. Young Physician award, and Teaching Award from the class of 2002 at Tufts University School of Medicine. Dr. Zhu was elected to the Fellow in American Academy of Neurology (FAAN) in 2019. He has over 40 peer reviewed publications in brain tumor research and has served as invited reviewers for many journals.
Disclosure: Boston Biomedical, Inc. (Self): Grant/Research Support; Five Prime (Self): Grant/Research Support; Novocure, Inc (Self): Grant/Research Support; Tocagen, inc (Self): Advisor or Review Panel member
Friday, November 22
11:50 AM – 12:00 PM
Saturday, November 23
2:45 PM – 2:50 PM